Premium
Diabetic macular oedema: evidence‐based treatment recommendations for Asian countries
Author(s) -
Cheung Gemmy CM,
Yoon Young Hee,
Chen Lee Jen,
Chen Shih Jen,
George Tara M,
Lai Timothy YY,
Park Kyu Hyung,
Tahija Sjakon G,
Uy Harvey S,
Wong Tien Y
Publication year - 2017
Publication title -
clinical and experimental ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.3
H-Index - 74
eISSN - 1442-9071
pISSN - 1442-6404
DOI - 10.1111/ceo.12999
Subject(s) - medicine , diabetic retinopathy , guideline , vascular endothelial growth factor , diabetic macular edema , clinical trial , macular degeneration , ophthalmology , diabetes mellitus , randomized controlled trial , intensive care medicine , surgery , vegf receptors , pathology , endocrinology
Diabetic macular oedema is the most common cause of diabetic retinopathy‐induced vision loss. Efficacy of anti‐vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized controlled trials. An Asian‐specific guideline for diabetic macular oedema treatment is needed as patients in Asia tend to present with far more advanced disease than seen elsewhere in the world. Previous reviews of diabetic macular oedema management lacked a broader assessment of anti‐vascular endothelial growth factor treatment choices and newer trials. Recent clinical trial data allow head‐to‐head comparisons between the different anti‐vascular endothelial growth factor agents and treatment regimens. This review aims to summarize the clinical evidence related to various treatment regimens for clinicians, with a focus on anti‐vascular endothelial growth factor therapies, and to provide guidance on the treatment of diabetic macular oedema in Asian patients.